Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jine S. van Bezooijen"'
Autor:
Frederik P. Bouw, Jine S. van Bezooijen, Eppo B. Wolvius, Maarten J. Koudstaal, Jifke F. Veenland, Erik Nout
Publikováno v:
Journal of Cranio-Maxillofacial Surgery, 43(6), 820-824. Churchill Livingstone
Little is known about the positional change of the Le Fort III segment following advancement. To study this, pre- and postoperative computed tomography scans of 18 craniosynosthosis patients were analyzed. The Le Fort III segment movement was measure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcc1575e50881ea625701aff8a6aaab4
https://pure.eur.nl/en/publications/cfdf2154-0425-4212-9edb-1518f733bbd4
https://pure.eur.nl/en/publications/cfdf2154-0425-4212-9edb-1518f733bbd4
Autor:
J.M.P.A. van den Reek, S.P. Menting, Errol P. Prens, C. I. Busard, Jine S. van Bezooijen, Martijn B. A. van Doorn, Phyllis I. Spuls, Elke de Jong, Barbara A. Hutten
Publikováno v:
Trials
Background The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met with conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2798d3d6c988a4f44e887ccd4cbeead8
http://europepmc.org/articles/PMC5341450
http://europepmc.org/articles/PMC5341450
Autor:
Karel G.H. van der Wal, Maarten J. Koudstaal, Eppo B. Wolvius, Erik Nout, Jifke F. Veenland, Wim C. J. Hop, Jine S. van Bezooijen
Publikováno v:
Journal of Cranio-Maxillofacial Surgery, 40(3), 223-228. Churchill Livingstone
Patients with syndromic craniosynostosis suffering from shallow orbits due to midface hypoplasia can be treated with a Le Fort III advancement osteotomy. This study evaluates the influence of Le Fort III advancement on orbital volume, position of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1812793874e4488aa567df03782077c
https://pure.eur.nl/en/publications/814aed2e-861f-43c6-9f0a-298cc2654201
https://pure.eur.nl/en/publications/814aed2e-861f-43c6-9f0a-298cc2654201
Autor:
Vincent H.J. van der Velden, Teun van Gelder, Martijn B. A. van Doorn, Mariska A. Bos, Ilona Bijen, Maarten L. Zandvliet, Marco W.J. Schreurs, Errol P. Prens, Jine S. van Bezooijen, Birgit C. P. Koch
Publikováno v:
Therapeutic Drug Monitoring, 35(5), 588-594
Therapeutic Drug Monitoring, 35(5), 588-594. Lippincott Williams & Wilkins
Therapeutic Drug Monitoring, 35(5), 588-594. Lippincott Williams & Wilkins
An increasing number of antigen-specific biologics have been introduced into clinical practice, and the ones that arrived first have already reached the end of their patented life span. Despite the use of these agents for over a decade, individualize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53095a41c6189b2d885077ab8ae8e388
https://hdl.handle.net/1887/101553
https://hdl.handle.net/1887/101553
